BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Mirxes inks new deals to scale adoption of early cancer detection solutions in APAC

August 22, 2023 | News

To address the escalating burden of cancer socially and economically in Indonesia and the underserved Southeast Asian population



Mirxes, a Singapore headquartered RNA technology company that is making diagnostic solutions for the early detection of diseases accessible on a global scale, has recently signed a partnership agreement and a Memorandum of Understanding (MoU) to contribute to the fight against cancer in the Asia Pacific (APAC) region.

Mirxes signed an MoU with Zhejiang Anji Economic Development District at the 17th Singapore-Zhejiang Economic and Trade Council (SZETC) meeting recently (*as seen in the image*), to pave the way for the scaling-up of its cancer early detection blood tests in China. This MoU will see Mirxes setting up a state-of-the-art in vitro diagnostic manufacturing plant in Zhejiang's Anji district. When operational, the plant will enable Mirxes China to scale annual production capacity of its cancer early detection tests to up to 100 million units and reduce unit production cost by 70%.

Further, Mirxes and PT ELION MEDIKA INDONESIA have signed a partnership agreement, witnessed by Singapore's Minister for Trade and Industry Gan Kim Yong and Indonesia's Coordinating Minister for Economic Affairs Airlangga Hartarto, at the sidelines of the 13th Singapore-Indonesia Six Bilateral Economic Working Groups Ministerial Meeting. The partnership agreement seeks to deepen the company's strategic partnership and expand into new areas of collaboration. Through this partnership, Mirxes and PT ELION will commercialise existing microRNA cancer blood tests, GASTROClear and LUNGClear, in Indonesia, which will be progressively locally manufactured to cater for the population in Indonesia, which has the fourth largest population in the world.

Mirxes will also embark on collaborations with Indonesian Institutes of Higher Learning and Public Health Institutes to conduct R&D for CADENCE-Indonesia, a joint development project for the optimisation and validation of a novel multi-cancer blood test for the Indonesian population. There are also plans to launch colorectal tests when ready.